RecruitingPhase 3NCT05756179
Effect of Diosmin and Hesperidin in Treatment of Patients With Rheumatoid Arthritis
Clinical Study Evaluating the Effect of Diosmin and Hesperidin in Treatment of Patients With Rheumatoid Arthritis
Sponsor
Alexandria University
Enrollment
80 participants
Start Date
Jul 18, 2023
Study Type
INTERVENTIONAL
Conditions
Summary
Evaluating the effect of the flavonoids combination (diosmin and hesperidin) as adjuvant therapy on patients with rheumatoid arthritis
Eligibility
Min Age: 19 YearsMax Age: 65 Years
Inclusion Criteria2
- Patients with mild to moderate disease activity.
- Patient age must be more than 18 years.
Exclusion Criteria3
- Pregnant and lactating females.
- Patients with liver, renal impairment or any other inflammatory diseases.
- Patients on TNF-α (tumor necrosis factor- α) or IL-1β (interleukin-1β) antagonists.
Interventions
DRUGDiosmin and Hesperidin Combination
Diosmin 450 mg and Hesperidin 50 mg Combination
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT05756179
Related Trials
Targeted Remotely-delivered Anti-inflammatory Interventions With Exercise for Rheumatoid Arthritis
NCT068415621 location
Nivolumab in Treating Patients With Autoimmune Disorders and Advanced, Metastatic, or Unresectable Cancer
NCT0381634552 locations
A Study Investigating the Efficacy and Safety of BGB-45035 Versus Placebo in Adults With Moderate to Severe Active Rheumatoid Arthritis
NCT0710093829 locations
A Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD5492 in Adult Participants With Systemic Lupus Erythematosus or Idiopathic Inflammatory Myopathies or Rheumatoid Arthritis.
NCT0691680633 locations
Biobank for Inflammatory Chronic Diseases and Osteoporosis
NCT050392161 location